お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
988467

バイオディフェンス (生物兵器防衛) の世界市場 - 業界分析と予測:2020年~2026年

Global Biodefense Market By Product (Anthrax, Smallpox, Botulism, Radiation/nuclear, and Other Products), By Region, Industry Analysis and Forecast, 2020 - 2026

出版日: | 発行: KBV Research | ページ情報: 英文 128 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=107.99円
バイオディフェンス (生物兵器防衛) の世界市場 - 業界分析と予測:2020年~2026年
出版日: 2021年01月29日
発行: KBV Research
ページ情報: 英文 128 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のバイオディフェンス (生物兵器防衛) の市場規模は、2026年までに175億米ドルに達し、予測期間中のCAGRで5.8%の成長が予測されています。市場は、有益な政府のイニシアチブ、政府の注目の高まり、バイオディフェンス戦略への資金提供など、さまざまな要因によって支えられています。

当レポートでは、世界のバイオディフェンス (生物兵器防衛) 市場について調査分析し、市場概要、市場規模・予測、セグメント別の市場分析、地域別の市場分析、競合情勢などについて、体系的な情報を提供しています。

目次

第1章 市場範囲と調査手法

第2章 市場概要

  • イントロダクション
  • 市場に影響を与える主な要因

第3章 競合分析:世界

  • 最近の業界における戦略的発展
  • 主要成功戦略

第4章 世界のバイオディフェンス (生物兵器防衛) 市場:製品別

  • 炭疽菌

第5章 世界のバイオディフェンス (生物兵器防衛) 市場:地域別

  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ・中東・アフリカ

第6章 企業プロファイル

  • Xoma Corporation
  • Altimmune, Inc.
  • Emergent BioSolutions, Inc.
  • Dynavax Technologies Corporation
  • SIGA Technologies, Inc.
  • Elusys Therapeutics, Inc.
  • Ichor Holdings, Ltd.
  • Cleveland BioLabs, Inc.
  • Bavarian Nordic A/S
  • Alnylam Pharmaceuticals, Inc.
図表

LIST OF TABLES

  • TABLE 1 Global Biodefense Market, 2016 - 2019, USD Million
  • TABLE 2 Global Biodefense Market, 2020 - 2026, USD Million
  • TABLE 3 Partnerships, Collaborations and Agreements- Biodefense Market
  • TABLE 4 Approvals- Biodefense Market
  • TABLE 5 Acquisition and Mergers- Biodefense Market
  • TABLE 6 Global Biodefense Market by Product, 2016 - 2019, USD Million
  • TABLE 7 Global Biodefense Market by Product, 2020 - 2026, USD Million
  • TABLE 8 Global Anthrax Market by Region, 2016 - 2019, USD Million
  • TABLE 9 Global Anthrax Market by Region, 2020 - 2026, USD Million
  • TABLE 10 Global Smallpox Market by Region, 2016 - 2019, USD Million
  • TABLE 11 Global Smallpox Market by Region, 2020 - 2026, USD Million
  • TABLE 12 Global Botulism Market by Region, 2016 - 2019, USD Million
  • TABLE 13 Global Botulism Market by Region, 2020 - 2026, USD Million
  • TABLE 14 Global Radiation/nuclear Market by Region, 2016 - 2019, USD Million
  • TABLE 15 Global Radiation/nuclear Market by Region, 2020 - 2026, USD Million
  • TABLE 16 Global Other Product Market by Region, 2016 - 2019, USD Million
  • TABLE 17 Global Other Product Market by Region, 2020 - 2026, USD Million
  • TABLE 18 Global Biodefense Market by Region, 2016 - 2019, USD Million
  • TABLE 19 Global Biodefense Market by Region, 2020 - 2026, USD Million
  • TABLE 20 North America Biodefense Market, 2016 - 2019, USD Million
  • TABLE 21 North America Biodefense Market, 2020 - 2026, USD Million
  • TABLE 22 North America Biodefense Market by Product, 2016 - 2019, USD Million
  • TABLE 23 North America Biodefense Market by Product, 2020 - 2026, USD Million
  • TABLE 24 North America Anthrax Market by Country, 2016 - 2019, USD Million
  • TABLE 25 North America Anthrax Market by Country, 2020 - 2026, USD Million
  • TABLE 26 North America Smallpox Market by Country, 2016 - 2019, USD Million
  • TABLE 27 North America Smallpox Market by Country, 2020 - 2026, USD Million
  • TABLE 28 North America Botulism Market by Country, 2016 - 2019, USD Million
  • TABLE 29 North America Botulism Market by Country, 2020 - 2026, USD Million
  • TABLE 30 North America Radiation/nuclear Market by Country, 2016 - 2019, USD Million
  • TABLE 31 North America Radiation/nuclear Market by Country, 2020 - 2026, USD Million
  • TABLE 32 North America Other Product Market by Country, 2016 - 2019, USD Million
  • TABLE 33 North America Other Product Market by Country, 2020 - 2026, USD Million
  • TABLE 34 North America Biodefense Market by Country, 2016 - 2019, USD Million
  • TABLE 35 North America Biodefense Market by Country, 2020 - 2026, USD Million
  • TABLE 36 US Biodefense Market, 2016 - 2019, USD Million
  • TABLE 37 US Biodefense Market, 2020 - 2026, USD Million
  • TABLE 38 US Biodefense Market by Product, 2016 - 2019, USD Million
  • TABLE 39 US Biodefense Market by Product, 2020 - 2026, USD Million
  • TABLE 40 Canada Biodefense Market, 2016 - 2019, USD Million
  • TABLE 41 Canada Biodefense Market, 2020 - 2026, USD Million
  • TABLE 42 Canada Biodefense Market by Product, 2016 - 2019, USD Million
  • TABLE 43 Canada Biodefense Market by Product, 2020 - 2026, USD Million
  • TABLE 44 Mexico Biodefense Market, 2016 - 2019, USD Million
  • TABLE 45 Mexico Biodefense Market, 2020 - 2026, USD Million
  • TABLE 46 Mexico Biodefense Market by Product, 2016 - 2019, USD Million
  • TABLE 47 Mexico Biodefense Market by Product, 2020 - 2026, USD Million
  • TABLE 48 Rest of North America Biodefense Market, 2016 - 2019, USD Million
  • TABLE 49 Rest of North America Biodefense Market, 2020 - 2026, USD Million
  • TABLE 50 Rest of North America Biodefense Market by Product, 2016 - 2019, USD Million
  • TABLE 51 Rest of North America Biodefense Market by Product, 2020 - 2026, USD Million
  • TABLE 52 Europe Biodefense Market, 2016 - 2019, USD Million
  • TABLE 53 Europe Biodefense Market, 2020 - 2026, USD Million
  • TABLE 54 Europe Biodefense Market by Product, 2016 - 2019, USD Million
  • TABLE 55 Europe Biodefense Market by Product, 2020 - 2026, USD Million
  • TABLE 56 Europe Anthrax Market by Country, 2016 - 2019, USD Million
  • TABLE 57 Europe Anthrax Market by Country, 2020 - 2026, USD Million
  • TABLE 58 Europe Smallpox Market by Country, 2016 - 2019, USD Million
  • TABLE 59 Europe Smallpox Market by Country, 2020 - 2026, USD Million
  • TABLE 60 Europe Botulism Market by Country, 2016 - 2019, USD Million
  • TABLE 61 Europe Botulism Market by Country, 2020 - 2026, USD Million
  • TABLE 62 Europe Radiation/nuclear Market by Country, 2016 - 2019, USD Million
  • TABLE 63 Europe Radiation/nuclear Market by Country, 2020 - 2026, USD Million
  • TABLE 64 Europe Other Product Market by Country, 2016 - 2019, USD Million
  • TABLE 65 Europe Other Product Market by Country, 2020 - 2026, USD Million
  • TABLE 66 Europe Biodefense Market by Country, 2016 - 2019, USD Million
  • TABLE 67 Europe Biodefense Market by Country, 2020 - 2026, USD Million
  • TABLE 68 Germany Biodefense Market, 2016 - 2019, USD Million
  • TABLE 69 Germany Biodefense Market, 2020 - 2026, USD Million
  • TABLE 70 Germany Biodefense Market by Product, 2016 - 2019, USD Million
  • TABLE 71 Germany Biodefense Market by Product, 2020 - 2026, USD Million
  • TABLE 72 UK Biodefense Market, 2016 - 2019, USD Million
  • TABLE 73 UK Biodefense Market, 2020 - 2026, USD Million
  • TABLE 74 UK Biodefense Market by Product, 2016 - 2019, USD Million
  • TABLE 75 UK Biodefense Market by Product, 2020 - 2026, USD Million
  • TABLE 76 France Biodefense Market, 2016 - 2019, USD Million
  • TABLE 77 France Biodefense Market, 2020 - 2026, USD Million
  • TABLE 78 France Biodefense Market by Product, 2016 - 2019, USD Million
  • TABLE 79 France Biodefense Market by Product, 2020 - 2026, USD Million
  • TABLE 80 Russia Biodefense Market, 2016 - 2019, USD Million
  • TABLE 81 Russia Biodefense Market, 2020 - 2026, USD Million
  • TABLE 82 Russia Biodefense Market by Product, 2016 - 2019, USD Million
  • TABLE 83 Russia Biodefense Market by Product, 2020 - 2026, USD Million
  • TABLE 84 Spain Biodefense Market, 2016 - 2019, USD Million
  • TABLE 85 Spain Biodefense Market, 2020 - 2026, USD Million
  • TABLE 86 Spain Biodefense Market by Product, 2016 - 2019, USD Million
  • TABLE 87 Spain Biodefense Market by Product, 2020 - 2026, USD Million
  • TABLE 88 Italy Biodefense Market, 2016 - 2019, USD Million
  • TABLE 89 Italy Biodefense Market, 2020 - 2026, USD Million
  • TABLE 90 Italy Biodefense Market by Product, 2016 - 2019, USD Million
  • TABLE 91 Italy Biodefense Market by Product, 2020 - 2026, USD Million
  • TABLE 92 Rest of Europe Biodefense Market, 2016 - 2019, USD Million
  • TABLE 93 Rest of Europe Biodefense Market, 2020 - 2026, USD Million
  • TABLE 94 Rest of Europe Biodefense Market by Product, 2016 - 2019, USD Million
  • TABLE 95 Rest of Europe Biodefense Market by Product, 2020 - 2026, USD Million
  • TABLE 96 Asia Pacific Biodefense Market, 2016 - 2019, USD Million
  • TABLE 97 Asia Pacific Biodefense Market, 2020 - 2026, USD Million
  • TABLE 98 Asia Pacific Biodefense Market by Product, 2016 - 2019, USD Million
  • TABLE 99 Asia Pacific Biodefense Market by Product, 2020 - 2026, USD Million
  • TABLE 100 Asia Pacific Anthrax Market by Country, 2016 - 2019, USD Million
  • TABLE 101 Asia Pacific Anthrax Market by Country, 2020 - 2026, USD Million
  • TABLE 102 Asia Pacific Smallpox Market by Country, 2016 - 2019, USD Million
  • TABLE 103 Asia Pacific Smallpox Market by Country, 2020 - 2026, USD Million
  • TABLE 104 Asia Pacific Botulism Market by Country, 2016 - 2019, USD Million
  • TABLE 105 Asia Pacific Botulism Market by Country, 2020 - 2026, USD Million
  • TABLE 106 Asia Pacific Radiation/nuclear Market by Country, 2016 - 2019, USD Million
  • TABLE 107 Asia Pacific Radiation/nuclear Market by Country, 2020 - 2026, USD Million
  • TABLE 108 Asia Pacific Other Product Market by Country, 2016 - 2019, USD Million
  • TABLE 109 Asia Pacific Other Product Market by Country, 2020 - 2026, USD Million
  • TABLE 110 Asia Pacific Biodefense Market by Country, 2016 - 2019, USD Million
  • TABLE 111 Asia Pacific Biodefense Market by Country, 2020 - 2026, USD Million
  • TABLE 112 China Biodefense Market, 2016 - 2019, USD Million
  • TABLE 113 China Biodefense Market, 2020 - 2026, USD Million
  • TABLE 114 China Biodefense Market by Product, 2016 - 2019, USD Million
  • TABLE 115 China Biodefense Market by Product, 2020 - 2026, USD Million
  • TABLE 116 Japan Biodefense Market, 2016 - 2019, USD Million
  • TABLE 117 Japan Biodefense Market, 2020 - 2026, USD Million
  • TABLE 118 Japan Biodefense Market by Product, 2016 - 2019, USD Million
  • TABLE 119 Japan Biodefense Market by Product, 2020 - 2026, USD Million
  • TABLE 120 India Biodefense Market, 2016 - 2019, USD Million
  • TABLE 121 India Biodefense Market, 2020 - 2026, USD Million
  • TABLE 122 India Biodefense Market by Product, 2016 - 2019, USD Million
  • TABLE 123 India Biodefense Market by Product, 2020 - 2026, USD Million
  • TABLE 124 South Korea Biodefense Market, 2016 - 2019, USD Million
  • TABLE 125 South Korea Biodefense Market, 2020 - 2026, USD Million
  • TABLE 126 South Korea Biodefense Market by Product, 2016 - 2019, USD Million
  • TABLE 127 South Korea Biodefense Market by Product, 2020 - 2026, USD Million
  • TABLE 128 Singapore Biodefense Market, 2016 - 2019, USD Million
  • TABLE 129 Singapore Biodefense Market, 2020 - 2026, USD Million
  • TABLE 130 Singapore Biodefense Market by Product, 2016 - 2019, USD Million
  • TABLE 131 Singapore Biodefense Market by Product, 2020 - 2026, USD Million
  • TABLE 132 Malaysia Biodefense Market, 2016 - 2019, USD Million
  • TABLE 133 Malaysia Biodefense Market, 2020 - 2026, USD Million
  • TABLE 134 Malaysia Biodefense Market by Product, 2016 - 2019, USD Million
  • TABLE 135 Malaysia Biodefense Market by Product, 2020 - 2026, USD Million
  • TABLE 136 Rest of Asia Pacific Biodefense Market, 2016 - 2019, USD Million
  • TABLE 137 Rest of Asia Pacific Biodefense Market, 2020 - 2026, USD Million
  • TABLE 138 Rest of Asia Pacific Biodefense Market by Product, 2016 - 2019, USD Million
  • TABLE 139 Rest of Asia Pacific Biodefense Market by Product, 2020 - 2026, USD Million
  • TABLE 140 LAMEA Biodefense Market, 2016 - 2019, USD Million
  • TABLE 141 LAMEA Biodefense Market, 2020 - 2026, USD Million
  • TABLE 142 LAMEA Biodefense Market by Product, 2016 - 2019, USD Million
  • TABLE 143 LAMEA Biodefense Market by Product, 2020 - 2026, USD Million
  • TABLE 144 LAMEA Anthrax Market by Country, 2016 - 2019, USD Million
  • TABLE 145 LAMEA Anthrax Market by Country, 2020 - 2026, USD Million
  • TABLE 146 LAMEA Smallpox Market by Country, 2016 - 2019, USD Million
  • TABLE 147 LAMEA Smallpox Market by Country, 2020 - 2026, USD Million
  • TABLE 148 LAMEA Botulism Market by Country, 2016 - 2019, USD Million
  • TABLE 149 LAMEA Botulism Market by Country, 2020 - 2026, USD Million
  • TABLE 150 LAMEA Radiation/nuclear Market by Country, 2016 - 2019, USD Million
  • TABLE 151 LAMEA Radiation/nuclear Market by Country, 2020 - 2026, USD Million
  • TABLE 152 LAMEA Other Product Market by Country, 2016 - 2019, USD Million
  • TABLE 153 LAMEA Other Product Market by Country, 2020 - 2026, USD Million
  • TABLE 154 LAMEA Biodefense Market by Country, 2016 - 2019, USD Million
  • TABLE 155 LAMEA Biodefense Market by Country, 2020 - 2026, USD Million
  • TABLE 156 Brazil Biodefense Market, 2016 - 2019, USD Million
  • TABLE 157 Brazil Biodefense Market, 2020 - 2026, USD Million
  • TABLE 158 Brazil Biodefense Market by Product, 2016 - 2019, USD Million
  • TABLE 159 Brazil Biodefense Market by Product, 2020 - 2026, USD Million
  • TABLE 160 Argentina Biodefense Market, 2016 - 2019, USD Million
  • TABLE 161 Argentina Biodefense Market, 2020 - 2026, USD Million
  • TABLE 162 Argentina Biodefense Market by Product, 2016 - 2019, USD Million
  • TABLE 163 Argentina Biodefense Market by Product, 2020 - 2026, USD Million
  • TABLE 164 UAE Biodefense Market, 2016 - 2019, USD Million
  • TABLE 165 UAE Biodefense Market, 2020 - 2026, USD Million
  • TABLE 166 UAE Biodefense Market by Product, 2016 - 2019, USD Million
  • TABLE 167 UAE Biodefense Market by Product, 2020 - 2026, USD Million
  • TABLE 168 Saudi Arabia Biodefense Market, 2016 - 2019, USD Million
  • TABLE 169 Saudi Arabia Biodefense Market, 2020 - 2026, USD Million
  • TABLE 170 Saudi Arabia Biodefense Market by Product, 2016 - 2019, USD Million
  • TABLE 171 Saudi Arabia Biodefense Market by Product, 2020 - 2026, USD Million
  • TABLE 172 South Africa Biodefense Market, 2016 - 2019, USD Million
  • TABLE 173 South Africa Biodefense Market, 2020 - 2026, USD Million
  • TABLE 174 South Africa Biodefense Market by Product, 2016 - 2019, USD Million
  • TABLE 175 South Africa Biodefense Market by Product, 2020 - 2026, USD Million
  • TABLE 176 Nigeria Biodefense Market, 2016 - 2019, USD Million
  • TABLE 177 Nigeria Biodefense Market, 2020 - 2026, USD Million
  • TABLE 178 Nigeria Biodefense Market by Product, 2016 - 2019, USD Million
  • TABLE 179 Nigeria Biodefense Market by Product, 2020 - 2026, USD Million
  • TABLE 180 Rest of LAMEA Biodefense Market, 2016 - 2019, USD Million
  • TABLE 181 Rest of LAMEA Biodefense Market, 2020 - 2026, USD Million
  • TABLE 182 Rest of LAMEA Biodefense Market by Product, 2016 - 2019, USD Million
  • TABLE 183 Rest of LAMEA Biodefense Market by Product, 2020 - 2026, USD Million
  • TABLE 184 Key Information -Xoma Corporation
  • TABLE 185 Key Information - Altimmune, Inc.
  • TABLE 186 Key Information - Emergent BioSolutions, Inc.
  • TABLE 187 Key Information - Dynavax Technologies Corporation
  • TABLE 188 Key Information - SIGA Technologies, Inc.
  • TABLE 189 key information - Elusys Therapeutics, Inc.
  • TABLE 190 key Information - Ichor Holdings, Ltd.
  • TABLE 191 Key Information - Cleveland BioLabs, Inc.
  • TABLE 192 key information - Bavarian Nordic A/S
  • TABLE 193 Key Information - Alnylam Pharmaceuticals, Inc.

List of Figures

  • FIG 1 Methodology for the research
  • FIG 2 Key Leading Strategies: Percentage Distribution (2016-2020)
  • FIG 3 Key Strategic Move: (Partnerships, Collaborations, and Agreements : 2017, Jul - 2020, Jul) Leading Players
  • FIG 4 Recent strategies and developments: Altimmune, Inc.
  • FIG 5 Recent strategies and developments: Emergent BioSolutions, Inc.
目次

The Global Biodefense Market size is expected to reach $17.5 billion by 2026, rising at a market growth of 5.8% CAGR during the forecast period. Biodefense refers to a group of medical or military steps that are adopted on account of re-establishing the biosecurity of a nation. Threats like biological toxins or infectious agents can be utilized with malicious intentions such as killing or infecting humans, animals, or the environment and to provoke biological warfare. There are various agents that are used for bioterrorism such as living organisms, like bacteria, viruses, fungi, and toxins.

In order to create social and economic turmoil, these agents can be utilized intentionally to infect and kill humans. The biodefense market is fueled by various factors such as beneficial government initiatives, increased government attention and funding towards biodefense strategies. Moreover, rising investment from private companies, and increasing prevalence of different agents like Flu, Ebola Virus, and Zika Virus also widen the scope of biodefense market in the years to come.

Over the last few years, genetic engineering and biotechnology have seen massive technological advancements, which have offered innovative ways to address these deadly and naturally occurring viruses that can be re-designed to create additional harm. Also, there is the easy availability of these organisms, which makes biodefense a significant aspect for countries across the globe. To carry out bioterrorism, various biological agents have been used such as botulism, anthrax, and chemical & nuclear agents, causing severe destruction.

By Product

Based on Product, the market is segmented into Anthrax, Smallpox, Botulism, Radiation/nuclear, and Other Products. The anthrax segment acquired the highest market share in 2019. The segment is anticipated to maintain a considerable CAGR during the forecast years. Anthrax is caused by bacillus anthracis, which is a gram-positive bacterium and it is one of the most preferred weapons against bioterrorism. These spores are largely favored as they can be easily transmitted into the environment by putting them in food, water, powder, and sprays.

By Region

Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. North America held the highest revenue share of the biodefense market in 2019. The region is also anticipated to exhibit a significant CAGR during the forecast years owing to the advancements in technology, the presence of massive federal investment, and increasing awareness among the population. Additionally, the presence of the leading players in this region is a positive factor for the market forecast.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Xoma Corporation, Altimmune, Inc., Emergent BioSolutions, Inc., Dynavax Technologies Corporation, SIGA Technologies, Inc., Elusys Therapeutics, Inc., Ichor Holdings, Ltd., Cleveland BioLabs, Inc., Bavarian Nordic A/S and Alnylam Pharmaceuticals, Inc.

Strategies deployed in Biodefense Market

Jul-2020: Altimmune came into collaboration with DynPort Vaccine Company, a General Dynamics Information Technology company. In this collaboration, they aimed to coordinate with U.S. Government funding efforts and deliver program management, regulatory support for AdCOVID, drug development activity integration, Altimmune's single-dose intranasal COVID-19 vaccine candidate.

Jun-2020: SIGA Technologies announced the deliveries of oral TPOXX to the U.S. Department of Health and Human Services.

Jun-2020: Ichor Medical Systems signed an agreement with Immunomic Therapeutics, a privately-held clinical-stage biotechnology company. This agreement aimed to support the development of ITI's investigational plasmid DNA vaccine therapy, ITI-1001.

Apr-2020: Emergent BioSolutions signed a partnership agreement with the U.S. government. The partnership focused on accelerating development of a plasma-derived therapy for patients with COVID-19. Emergent received $14.5 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health & Human Services (HHS), to assist its COVID-HIG program, one of two hyperimmune development programs announced by Emergent.

Mar-2020: SIGA Technologies came into collaboration with Turnstone Biologics, a privately-held immuno-oncology company. The collaboration aimed to provide TPOXX in connection with Turnstone's proprietary SKV vaccinia oncolytic immunotherapy platform. The platform uses vaccinia viruses made for expanded selectivity and safety and high-potency immune stimulation, and offer the delivery of multiple therapeutic agents directly to tumors. The collaboration also offer Turnstone with access to SIGA's TPOXX oral antiviral capsules for its use in future clinical programs.

Sep-2019: Bavarian Nordic got the approval of JYNNEOS and Monkeypox Vaccine by the U.S. Food and Drug Administration (FDA). JYNNEOS prevents smallpox and monkeypox disease in adults and older, determined to be at high risk for smallpox or monkeypox infection. It is the only approved non-replicating smallpox vaccine in the U.S. and the only approved monkeypox vaccine in the world.

Sep-2019: Emergent BioSolutions received $20 million to develop and manufacture an auto-injector including diazepam to cure nerve agent-induced seizures for U.S. Department of Defense. Emergent's device aimed for intramuscular buddy-administration to utilize it in military environments and for civilian emergencies.

Jul-2019: Altimmune took over Spitfire Pharma, a California drug developer. Under this acquisition, Spitfire's flagship product, a treatment for nonalcoholic steatohepatitis, or NASH, a condition marked by fat buildup in the liver integrated with Altimmune's pipeline of flu and anthrax vaccines.

Jul-2019: SIGA Technologies signed a multi-year contract from the United States Department of Defense (DoD). The contract aimed to assist work necessary to earn a potential label expansion for TPOXX that included Post-Exposure Prophylaxis (PEP) of smallpox.

Mar-2019: Ichor Medical Systems collaborated with AstraZeneca, a British-Swedish multinational pharmaceutical and biopharmaceutical company. The collaboration focused on the development and clinical assessment of plasmid DNA constructs. Moreover Ichor received upfront and annual payments along with development milestones.

Sep-2018: SIGA Technologies entered into a multi-year contract with the Biomedical Advanced Research and Development Authority (BARDA), a part of the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response. The contract aimed to deliver oral and intravenous formulations of TPOXX to the Strategic National Stockpile.

Aug-2018: Cleveland BioLabs established a 50-50 joint venture, named Genome Protection, Inc. (GPI). This joint venture is the result of agreement of Cleveland BioLabs and Everon BioSciences, Inc. (Everon). GPI's aimed to develop and commercialize drugs for anti-aging applications capable of prolonging human health and life-span. Moreover, GPI announced an agreement for Future Equity (SAFE) with venture capital fund Norma Investments Limited (Norma). Under the SAFE, GPI granted Norma the right to purchase shares of GPI's capital stock in exchange for the payment of up to $30 million, of which $10.5 million was paid shortly after the execution of the SAFE.

Jul-2018: SIGA Technologies announced that its oral TPOXX got the approval from the U.S. Food and Drug Administration (FDA), which treat smallpox to mitigate the impact of a potential outbreak.

Oct-2017: Emergent BioSolutions acquired Sanofi's ACAM2000 business, which includes ACAM2000, the only smallpox vaccine approved by the U.S. Food and Drug Administration. Under this acquisition, Emergent aimed to assume responsibility for its existing contract with the Centers for Disease Control and Prevention (CDC), offering ACAM2000 to the Strategic National Stockpile (SNS).

Sep-2017: Bavarian Nordic entered into a contract with the Biomedical Advanced Research and Development Authority (BARDA). The contract was focused on providing its freeze-dried Imvamune smallpox vaccine for the U.S. Strategic National Stockpile.

Jul-2017: Emergent BioSolutions signed an agreement with GSK, a leading healthcare company. This agreement aimed to acquire raxibacumab, a fully human monoclonal antibody approved by the U.S. Food and Drug Administration (FDA) for the curing and preventing inhalational anthrax. The acquisition strengthened their leadership position in the market and expanded it franchise of vaccines and therapeutics addressing Category A bioterrorism threats.

Scope of the Study

Market Segmentation:

By Product

  • Anthrax
  • Smallpox
  • Botulism
  • Radiation/nuclear,
  • Other Products

By Geography

  • North America

US

Canada

Mexico

Rest of North America

  • Europe

Germany

UK

France

Russia

Spain

Italy

Rest of Europe

  • Asia Pacific

China

Japan

India

South Korea

Singapore

Malaysia

Rest of Asia Pacific

  • LAMEA

Brazil

Argentina

UAE

Saudi Arabia

South Africa

Nigeria

Rest of LAMEA

Companies Profiled

  • Xoma Corporation
  • Altimmune, Inc.
  • Emergent BioSolutions, Inc.
  • Dynavax Technologies Corporation
  • SIGA Technologies, Inc.
  • Elusys Therapeutics, Inc.
  • Ichor Holdings, Ltd.
  • Cleveland BioLabs, Inc.
  • Bavarian Nordic A/S
  • Alnylam Pharmaceuticals, Inc.

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 Global Biodefense Market, by Product
    • 1.4.2 Global Biodefense Market, by Geography
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
    • 2.1.2 Market Composition and Scenario
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. Competition Analysis - Global

  • 3.1 Recent Industry Wide Strategic Developments
    • 3.1.1 Partnerships, Collaborations and Agreements
    • 3.1.2 Approvals
    • 3.1.3 Acquisition and Mergers
  • 3.2 Top Winning Strategies
    • 3.2.1 Key Leading Strategies: Percentage Distribution (2016-2020)
    • 3.2.2 Key Strategic Move: (Partnerships, Collaborations, and Agreements : 2017, Jul - 2020, Jul) Leading Players

Chapter 4. Global Biodefense Market by Product

  • 4.1 Global Anthrax Market by Region
    • 4.1.1 Global Smallpox Market by Region
    • 4.1.2 Global Botulism Market by Region
    • 4.1.3 Global Radiation/nuclear Market by Region
    • 4.1.4 Global Other Product Market by Region

Chapter 5. Global Biodefense Market by Region

  • 5.1 North America Biodefense Market
    • 5.1.1 North America Biodefense Market by Product
      • 5.1.1.1 North America Anthrax Market by Country
      • 5.1.1.2 North America Smallpox Market by Country
      • 5.1.1.3 North America Botulism Market by Country
      • 5.1.1.4 North America Radiation/nuclear Market by Country
      • 5.1.1.5 North America Other Product Market by Country
    • 5.1.2 North America Biodefense Market by Country
      • 5.1.2.1 US Biodefense Market
        • 5.1.2.1.1 US Biodefense Market by Product
      • 5.1.2.2 Canada Biodefense Market
        • 5.1.2.2.1 Canada Biodefense Market by Product
      • 5.1.2.3 Mexico Biodefense Market
        • 5.1.2.3.1 Mexico Biodefense Market by Product
      • 5.1.2.4 Rest of North America Biodefense Market
        • 5.1.2.4.1 Rest of North America Biodefense Market by Product
  • 5.2 Europe Biodefense Market
    • 5.2.1 Europe Biodefense Market by Product
      • 5.2.1.1 Europe Anthrax Market by Country
      • 5.2.1.2 Europe Smallpox Market by Country
      • 5.2.1.3 Europe Botulism Market by Country
      • 5.2.1.4 Europe Radiation/nuclear Market by Country
      • 5.2.1.5 Europe Other Product Market by Country
    • 5.2.2 Europe Biodefense Market by Country
      • 5.2.2.1 Germany Biodefense Market
        • 5.2.2.1.1 Germany Biodefense Market by Product
      • 5.2.2.2 UK Biodefense Market
        • 5.2.2.2.1 UK Biodefense Market by Product
      • 5.2.2.3 France Biodefense Market
        • 5.2.2.3.1 France Biodefense Market by Product
      • 5.2.2.4 Russia Biodefense Market
        • 5.2.2.4.1 Russia Biodefense Market by Product
      • 5.2.2.5 Spain Biodefense Market
        • 5.2.2.5.1 Spain Biodefense Market by Product
      • 5.2.2.6 Italy Biodefense Market
        • 5.2.2.6.1 Italy Biodefense Market by Product
      • 5.2.2.7 Rest of Europe Biodefense Market
        • 5.2.2.7.1 Rest of Europe Biodefense Market by Product
  • 5.3 Asia Pacific Biodefense Market
    • 5.3.1 Asia Pacific Biodefense Market by Product
      • 5.3.1.1 Asia Pacific Anthrax Market by Country
      • 5.3.1.2 Asia Pacific Smallpox Market by Country
      • 5.3.1.3 Asia Pacific Botulism Market by Country
      • 5.3.1.4 Asia Pacific Radiation/nuclear Market by Country
      • 5.3.1.5 Asia Pacific Other Product Market by Country
    • 5.3.2 Asia Pacific Biodefense Market by Country
      • 5.3.2.1 China Biodefense Market
        • 5.3.2.1.1 China Biodefense Market by Product
      • 5.3.2.2 Japan Biodefense Market
        • 5.3.2.2.1 Japan Biodefense Market by Product
      • 5.3.2.3 India Biodefense Market
        • 5.3.2.3.1 India Biodefense Market by Product
      • 5.3.2.4 South Korea Biodefense Market
        • 5.3.2.4.1 South Korea Biodefense Market by Product
      • 5.3.2.5 Singapore Biodefense Market
        • 5.3.2.5.1 Singapore Biodefense Market by Product
      • 5.3.2.6 Malaysia Biodefense Market
        • 5.3.2.6.1 Malaysia Biodefense Market by Product
      • 5.3.2.7 Rest of Asia Pacific Biodefense Market
        • 5.3.2.7.1 Rest of Asia Pacific Biodefense Market by Product
  • 5.4 LAMEA Biodefense Market
    • 5.4.1 LAMEA Biodefense Market by Product
      • 5.4.1.1 LAMEA Anthrax Market by Country
      • 5.4.1.2 LAMEA Smallpox Market by Country
      • 5.4.1.3 LAMEA Botulism Market by Country
      • 5.4.1.4 LAMEA Radiation/nuclear Market by Country
      • 5.4.1.5 LAMEA Other Product Market by Country
    • 5.4.2 LAMEA Biodefense Market by Country
      • 5.4.2.1 Brazil Biodefense Market
        • 5.4.2.1.1 Brazil Biodefense Market by Product
      • 5.4.2.2 Argentina Biodefense Market
        • 5.4.2.2.1 Argentina Biodefense Market by Product
      • 5.4.2.3 UAE Biodefense Market
        • 5.4.2.3.1 UAE Biodefense Market by Product
      • 5.4.2.4 Saudi Arabia Biodefense Market
        • 5.4.2.4.1 Saudi Arabia Biodefense Market by Product
      • 5.4.2.5 South Africa Biodefense Market
        • 5.4.2.5.1 South Africa Biodefense Market by Product
      • 5.4.2.6 Nigeria Biodefense Market
        • 5.4.2.6.1 Nigeria Biodefense Market by Product
      • 5.4.2.7 Rest of LAMEA Biodefense Market
        • 5.4.2.7.1 Rest of LAMEA Biodefense Market by Product

Chapter 6. Company Profiles

  • 6.1 Xoma Corporation
    • 6.1.1 Company Overview
    • 6.1.2 Financial Analysis
    • 6.1.3 Regional Analysis
    • 6.1.4 Research & Development Expense
  • 6.2 Altimmune, Inc.
    • 6.2.1 Company Overview
    • 6.2.2 Financial Analysis
    • 6.2.3 Research & Development Expense
    • 6.2.4 Recent strategies and developments:
      • 6.2.4.1 Acquisition and Mergers:
      • 6.2.4.2 Partnerships, Collaborations, and Agreements:
  • 6.3 Emergent BioSolutions, Inc.
    • 6.3.1 Company Overview
    • 6.3.2 Financial Analysis
    • 6.3.3 Research & Development Expense
    • 6.3.4 Recent strategies and developments:
      • 6.3.4.1 Acquisition and Mergers:
      • 6.3.4.2 Partnerships, Collaborations, and Agreements:
  • 6.4 Dynavax Technologies Corporation
    • 6.4.1 Company Overview
    • 6.4.2 Financial Analysis
    • 6.4.3 Research & Development Expense
  • 6.5 SIGA Technologies, Inc.
    • 6.5.1 Company Overview
    • 6.5.2 Financial Analysis
    • 6.5.3 Research & Development Expense
    • 6.5.4 Recent strategies and developments:
      • 6.5.4.1 Partnerships, Collaborations, and Agreements:
      • 6.5.4.2 Approvals:
  • 6.6 Elusys Therapeutics, Inc.
    • 6.6.1 Company Overview
    • 6.6.2 Recent strategies and developments:
      • 6.6.2.1 Approvals:
  • 6.7 Ichor Holdings, Ltd.
    • 6.7.1 Company Overview
    • 6.7.2 Financial Analysis
    • 6.7.3 Regional Analysis
    • 6.7.4 Research & Development Expense
    • 6.7.5 Recent strategies and developments:
      • 6.7.5.1 Partnerships, Collaborations, and Agreements:
  • 6.8 Cleveland BioLabs, Inc.
    • 6.8.1 Company Overview
    • 6.8.2 Financial Analysis
    • 6.8.3 Research & Development Expense
    • 6.8.4 Recent strategies and developments:
      • 6.8.4.1 Partnerships, Collaborations, and Agreements:
  • 6.9 Bavarian Nordic A/S
    • 6.9.1 Company Overview
    • 6.9.2 Financial Analysis
    • 6.9.3 Regional Analysis
    • 6.9.4 Research & Development Expense
    • 6.9.5 Recent strategies and developments:
      • 6.9.5.1 Partnerships, Collaborations, and Agreements:
      • 6.9.5.2 Approvals:
  • 6.10. Alnylam Pharmaceuticals, Inc.
    • 6.10.1 Company Overview
    • 6.10.2 Financial Analysis
    • 6.10.3 Research & Development Expense
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.